




Searching News Database: natalizumab
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
HSMN NewsFeed - 23 Jul 2007
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
HSMN NewsFeed - 18 Jun 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality
HSMN NewsFeed - 5 Jun 2006
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
HSMN NewsFeed - 28 Apr 2006
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
HSMN NewsFeed - 29 Mar 2006
Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis
Biogen Idec and Elan Announce Re-Initiation of TYSABRI(R) Clinical Trial Dosing in Multiple Sclerosis
Additional items found! 29

Members Archive contains
29 additional stories matching:
natalizumab
(Password required)
natalizumab
(Password required)